Cashing in on Qnexa

Despite the ups and downs of Vivus Inc. (NASDAQ:VVUS) over the past few years, some investments in the obesity play are looking at tidy gains after last week's positive FDA panel vote on Qnexa (see Cover Story).

The biotech last week added $901 million to its market cap to reach $2 billion. The stock finished the week up $10.14 (85%) to $22.13. The price is well above the stock's last peak of $13.20 on May 18, 2010, a few months before a first panel rebuffed Qnexa in July that year...